Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

649 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker.
Besson D, Pavageau AH, Valo I, Bourreau A, Bélanger A, Eymerit-Morin C, Moulière A, Chassevent A, Boisdron-Celle M, Morel A, Solassol J, Campone M, Gamelin E, Barré B, Coqueret O, Guette C. Besson D, et al. Among authors: morel a. Mol Cell Proteomics. 2011 Dec;10(12):M111.009712. doi: 10.1074/mcp.M111.009712. Epub 2011 Oct 10. Mol Cell Proteomics. 2011. PMID: 21986994 Free PMC article.
Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR method. Implications for pretherapeutic determination of tumor resistance phenotype.
Barbado M, Preisser L, Boisdron-Celle M, Verriele V, Lorimier G, Gamelin E, Morel A. Barbado M, et al. Among authors: morel a. Cancer Lett. 2006 Oct 28;242(2):168-79. doi: 10.1016/j.canlet.2005.11.008. Epub 2006 Jan 4. Cancer Lett. 2006. PMID: 16387426 Free article.
Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
Rouits E, Charasson V, Pétain A, Boisdron-Celle M, Delord JP, Fonck M, Laurand A, Poirier AL, Morel A, Chatelut E, Robert J, Gamelin E. Rouits E, et al. Among authors: morel a. Br J Cancer. 2008 Oct 21;99(8):1239-45. doi: 10.1038/sj.bjc.6604673. Epub 2008 Sep 16. Br J Cancer. 2008. PMID: 18797458 Free PMC article. Clinical Trial.
Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma.
Morel A, Boisdron-Celle M, Fey L, Lainé-Cessac P, Gamelin E. Morel A, et al. Clin Biochem. 2007 Jan;40(1-2):11-7. doi: 10.1016/j.clinbiochem.2006.07.012. Epub 2006 Sep 1. Clin Biochem. 2007. PMID: 17046731
Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer.
Cellier P, Leduc B, Martin L, Vié B, Chevelle C, Vendrely V, Salemkour A, Carrie C, Calais G, Burtin P, Campion L, Boisdron-Celle M, Morel A, Berger V, Gamelin E. Cellier P, et al. Among authors: morel a. BMC Cancer. 2011 Mar 16;11:98. doi: 10.1186/1471-2407-11-98. BMC Cancer. 2011. PMID: 21410976 Free PMC article. Clinical Trial.
Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience.
Blons H, Rouleau E, Charrier N, Chatellier G, Côté JF, Pages JC, de Fraipont F, Boyer JC, Merlio JP, Morel A, Gorisse MC, de Cremoux P, Leroy K, Milano G, Ouafik L, Merlin JL, Le Corre D, Aucouturier P, Sabourin JC, Nowak F, Frebourg T, Emile JF, Durand-Zaleski I, Laurent-Puig P; MOKAECM Collaborative Group. Blons H, et al. Among authors: morel a. PLoS One. 2013 Jul 25;8(7):e68945. doi: 10.1371/journal.pone.0068945. Print 2013. PLoS One. 2013. PMID: 23935912 Free PMC article.
649 results